(Q44500169)

3 December 2017

title

Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression (English)

1 reference

3 December 2017

1 reference

1 reference

Michael A Kaliner

1

1 reference

3 December 2017

Martha V White

2

1 reference

3 December 2017

Athena Economides

3

1 reference

3 December 2017

Tera Crisalida

4

1 reference

3 December 2017

Mary Hale

5

1 reference

3 December 2017

Yuning Liao

6

1 reference

3 December 2017

Claire D Christian

7

1 reference

3 December 2017

George C Georges

8

1 reference

3 December 2017

Thomas H Woodworth

9

1 reference

3 December 2017

Suzanne G Meeves

10

1 reference

3 December 2017

publication date

1 June 2003

1 reference

Annals of Allergy, Asthma & Immunology

3 December 2017

published in

1 reference

3 December 2017

volume

90

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

629-634

1 reference

Second-generation antihistamines: a comparative review

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

New insights into the second generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Peripheral H1-blockade effect of fexofenadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Skin concentrations of H1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961867-4

7 January 2021

10.1016/S1081-1206(10)61867-4

Identifiers

DOI

1 reference

3 December 2017

1 reference